Nuclear Waste from Manhattan Project Transformed into Breakthrough Cancer Treatment at Oak Ridge

Scientists at Oak Ridge National Laboratory (search)Search term in Tennessee are transforming nuclear waste from the Manhattan Project into a promising cancer treatment, marking a significant breakthrough in targeted alpha therapy. The facility, once the headquarters where the world's first atomic bomb was created, is now extracting Thorium-229 from decades-old uranium stockpiles to develop precision cancer treatments.

Revolutionary Cancer Treatment from Nuclear Waste

The innovative process involves extracting Thorium-229 from Uranium-233, radioactive material that has been stored at Oak Ridge since the 1940s. Nuclear power company TerraPower (search)Search term and Energy Department contractor AtkinsRealis Isotek (search)Search term have developed the extraction method as part of the uranium disposal process.

"Isotek is taking the government supply of Uranium-233, and we are processing it ultimately for disposal," an Isotek spokeswoman explained. "But during that process we are extracting Thorium-229."

The extracted Thorium-229 produces Actinium-225 (Ac-225), a radioactive isotope that forms the basis of targeted alpha therapy. This cutting-edge treatment works like a guided missile, with specialized antibodies acting as homing devices that seek out and attach to cancer cells in the prostate, breast, or lymph nodes.

Precision Treatment with Minimal Side Effects

Targeted alpha therapy represents a significant advancement over traditional cancer treatments. When Ac-225 attaches to cancer cells, it releases alpha particles that break down the cancer cell's DNA and destroy tumors without affecting surrounding healthy tissue. This precision approach results in fewer side effects compared to broader treatments like chemotherapy.

Researchers believe the therapy could treat multiple cancer types, including lymphoma, prostate cancer, and breast cancer. Sarah Schaefer, project manager for Oak Ridge's uranium cleanup effort, emphasized the immediacy of this development: "This is no longer something that will happen in the future. The time is now."

Addressing Global Supply Scarcity

The treatment faces a critical supply challenge, as only 45 grams of Thorium-229 exist worldwide—equivalent to about six metal washers or 1.6 ounces. Despite this scarcity, the material's potency means even microscopic amounts can treat patients effectively. A single therapeutic dose of Ac-225 typically ranges from four to 50 MBq (megabecquerels), requiring less than a grain of salt's worth of Thorium-229.

"It's important to extract Th-229 because that isotope only comes from U-233," Schaefer noted. "Most of the world's supply of U-233 is stored at ORNL, so once this material is dispositioned, no more Th-229 will be available."

Clinical Progress and Market Timeline

The public-private partnership has enabled significantly increased production while reducing costs and eliminating risks by removing highly enriched fissile material from storage. One drug utilizing this technology is already in phase III clinical trials and could reach market by the second half of 2027.

Future Production Challenges

Oak Ridge has set a target date of 2028 for eliminating their entire Uranium-233 inventory, creating urgency around developing alternative production methods. Scientists are exploring manufacturing Thorium-229 from alternatives like Radium-226 in nuclear reactors, where neutrons would bombard the material to change its atomic structure.

Another approach involves using particle accelerators called cyclotrons to fire protons at Radium-226 or Thorium-232, essentially carving out the needed radioactive material through high-tech precision tools. These methods would provide sustainable production pathways once the Manhattan Project waste supply is exhausted.